//www.makeeyeware.comInsight
//www.makeeyeware.comTaplow
//www.makeeyeware.comKnowledge
  • News
  • Cases
  • Downloads
The Truth of Leadership below the Iceberg
03.01.2019

The Truth of Leadership below the Iceberg

The Taplow - China and Human Smart embarked on a fantastic journey to explore the truth of leadership below the “iceberg” in Beijing.
US Team welcomes it's new members
23.12.2018

US Team welcomes it's new members

美国管理合伙人史蒂夫•群落是骄傲的announce that two new colleges have joined our USA team

International Executive Search Taplow Consulting France expands its services with Interim Management.
17.12.2018

International Executive Search Taplow Consulting France expands its services with Interim Management.

For nearly 10 years, two human resources consulting firms, Taplow Consulting France, expert in Executive Search, coaching and management...
First 8 9 10 11 12 13 14 15 16 17 Last

首席执行官的运动:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contacTimo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contactSangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here